Klinická účinnost a bezpečnost bazálního inzulinového analoga glarginu v léčbě pacientů s diabetes mellitus 2. typu - editorial

Alena Adamíková

Vnitr Lek 2016, 62(9):688-689  

Hereditární angioedém (HAE, D 84.1) - charakteristika péče v České republice - editorial

Irena Krčmová

Vnitr Lek 2016, 62(9):690-691  

Clinically relevant possibilities and limits of differential diagnosis of megaloblastic anemia and myelodysplastic syndrome - refractory anemia type in bone marrow biopsies

Petra Vašeková, Peter Szépe, Ján Marcinek, Tomáš Balhárek, Lukáš Plank

Vnitr Lek 2016, 62(9):692-697  

Introduction:Megaloblastic anemia (MA) represents a subtype of macrocytic anemia caused by impaired DNA synthesis, mostly due to folate and vitamin B₁₂ deficiency. Its mildest forms lead to macrocytosis without concomitant anemia, but more severe forms to thrombocytopenia and/or leucopenia as well. In majority of the cases, the diagnosis of MA dose not represent a serious clinical problem, however, other causes of macrocytosis including myelodysplastic syndrome (MDS) must be excluded. Material and methods:In the period 2004-2015 we identified in our registry 126 consecutive bone marrow (BM) biopsies of patients...

Jak postupovat při podezření na sekundární arteriální hypertenzi

Tomáš Zelinka, Jiří Widimský jr, Jiří Ceral, Jan Filipovský

Vnitr Lek 2016, 62(9):740-745  

Oral anticoagulants for primary and secondary prevention of venous thromboembolism

Peter Gavorník, Andrej Dukát, Ľudovít Gašpar, Gabriela Gubo, Naďa Hučková

Vnitr Lek 2016, 62(9):746-750  

Until recently, vitamin K antagonists (VKA; predominantly warfarin) were the only oral anticoagulants for primary and secondary prevention of venous thromboembolism. Prevention and therapy with novel, direct, non-VKA oral anticoagulant agents (NOACs; DOACs: dabigatran, rivaroxaban, apixaban, edoxaban), have recently become available as an alternative to VKA. NOACs have been shown to be non-inferior or superior to VKA in clinical trials. Available results suggest that real world safety of NOACs is mostly consistent with results observed in clinical trials. The most effective method is triple simultaneous prevention of venous thromboembolism (pharmacokineziome...

Current position of a fixed combination telmisartan with amlodipine in treatment of essential arterial hypertension

Jiří Slíva

Vnitr Lek 2016, 62(9):699-702  

Nowadays, fixed drug combinations are very important part of pharmacotherapy in essential arterial hypertension. The ameliorated activity of RAAS system (ACE inhibitors or sartans) along with calcium-ion channel inhibitor results in additive decrease of blood pressure with concomitant beneficial safety profile. Both telmisartan and amlodipine possess very favorable pharmacological properties, what is reflected in results of performed clinical trials, in which they were used as combinations.

Clinical efficacy and safety of basal insulin analogue glargine in patients with type 2 diabetes mellitus

Milan Flekač, Jan Šoupal

Vnitr Lek 2016, 62(9):705-711  

Basal insulin has a clearly defined position in the recommendations for the treatment of patients with type 2 diabetes mellitus. General most common indication for administration is the addition in situation of the failure of noninsulin antidiabetic therapy or early insulin treatment of diabetes, as one of the second choice after metformin. In the recent years there is significant expansion of the range of antidiabetic drugs, including basal insulin analogues. In connection with the introduction of concentrated long-acting basal insulin analogues into the clinical practice many questions regarding clinical efficacy and safety raises especially comparing...

Schnitzler's Syndrome. Differential diagnostics, an overview of therapeutic options and description of 5 cases treated with anakinra

Zdeněk Adam, Anna Šedivá, Renata Koukalová, Zdeněk Řehák, Hana Petrášová, Petr Szturz, Zdenka Adamová, Eva Vetešníková, Luděk Pour, Marta Krejčí, Viera Sandecká, Eva Pourová, Zdeňka Čermáková, Sabina Ševčíková, Zdeněk Král, Jiří Mayer

Vnitr Lek 2016, 62(9):713-727  

Schnitzler's syndrome is an acquired auto-inflammatory disease of still unclear origin. The Strasbourg criteria were adopted (non-infectious fever, chronic urticaria, changes in the bone structure, leukocytosis and higher values of inflammatory markers - CRP and presence of monoclonal immunoglobulin mostly of type IgM, very rarely of IgG) to establish this diagnosis. The first-choice therapy for this disease is the blocking of interleukin-1 effects. In practice, the interleukin-1 receptor antagonist, anakinra, is the most commonly used. Currently reports also appear of the use of other medicines blocking the effect of interleukin-1, namely canakinumab...

Arrhythmogenic left ventricular cardiomyopathy

Štěpán Havránek, Tomáš Paleček, Petr Kuchynka, Ivana Vítková

Vnitr Lek 2016, 62(9):728-735  

Arrhythmogenic left ventricular cardiomyopathy (ALVC) is a rare condition characterised by progressive fibrofatty replacement of the myocardium of the left ventricle in combination with arrhythmias of left ventricular origin. ALVC has been linked to autosomal dominant mutations of genes encoding desmosomal proteins, similarly to the classic arrhythmogenic right ventricular cardiomyopathy with which it also shares pathological and prognostic features. It seems that isolated left or right ventricular abnormalities represent two extremes of the spectrum of clinical manifestations of a single disease: arrhythmogenic cardiomyopathy. In addition to arrhythmias...

Current treatment options for hereditary angioedema

Roman Hakl

Vnitr Lek 2016, 62(9):736-739  

Hereditary angioedema (HAE) caused by C1-inhibitor deficiency is a rare autosomal dominant disease. Clinically, HAE is manifested by repeated episodes of localized subcutaneous or submucosal edema. The disease is disabling and can be lethal. There is an extreme variability in frequency and severity of symptoms. This article concerns on the organization of care and current treatment options of the disease. Treatment strategy includes short-term and long-term prophylaxis and treatment of attacks. Currently, treatment options include attenuated androgens, antifibrinolytics, recombinant (rhC1-INH) and plasma-derived (pdC1-INH) C1-INH, bradykinin receptor...

Intenzifikované režimy léčby chronického selhání ledvin v domácím prostředí

Michaela Ságová

Vnitr Lek 2016, 62(9):757-761  

In memoriam pana profesora Karla Horkého

Vnitr Lek 2016, 62(9):683  

Najnovšie trendy v internej medicíne nielen v Čechách a na Slovensku. Správa z XI. kongresu internej medicíny

Michal Pečík

Vnitr Lek 2016, 62(9):751-753  

36. světový kongres Mezinárodní společnosti pro hematologii

Petr Lemež

Vnitr Lek 2016, 62(9):754-756